What will new weight loss medicines bring to people with type 2 diabetes?
While the new generation of available weight management medications are the most effective...
Read MoreOct 5, 2026 | Media, Research, Uncategorized
While the new generation of available weight management medications are the most effective...
Read MoreSep 30, 2026 | Research, Uncategorized
As blogged previously, the TRIUMPH-1 study of retatrutide demonstrated previously unsurpassed...
Read MoreSep 24, 2026 | Uncategorized
In the ‘old days’ – really only up until 5 years ago! – when we had only...
Read MoreSep 21, 2026 | Uncategorized
The target metric long required by regulatory agencies (American FDA, Health Canada, European...
Read MoreSep 18, 2026 | Uncategorized
About one in three adults who grew up before the chickenpox vaccine era (which started around year...
Read MoreSep 14, 2026 | Uncategorized
Sarcopenia, defined as low muscle mass with loss of strength and/or function, is associated with...
Read MoreSep 7, 2026 | Uncategorized
Prediabetes is extremely common, affecting 14-37% of people with obesity (depending on the...
Read MoreAug 20, 2026 | Uncategorized
As blogged previously, GLP-1 based medications can sometimes cause dysesthesia, meaning unusual or...
Read MoreAug 16, 2026 | Uncategorized
As blogged previously, there are many medications that need to be considered for monitoring and...
Read MoreAug 7, 2026 | Media, Uncategorized
Well this is a first in the obesity world. In USA, the FDA has provided guidance to drugmaker Eli...
Read MoreJul 27, 2026 | Media, Uncategorized
As blogged previously, retatrutide is a GLP1, glucagon, and GIP (‘triple G’) agonist...
Read MoreJul 23, 2026 | Media, Uncategorized
There’s a lot of chatter in the virtual space these days about microdosing GLP1 medicines...
Read MoreJul 17, 2026 | Research, Uncategorized
Acquired hypothalamic obesity (AHO) is a rare and particularly challenging form of obesity to...
Read MoreJul 4, 2026 | Media, Uncategorized
Hot on the heels of the first generic Ozempics (semaglutide for type 2 diabetes), the first...
Read More

I am a medical doctor, Specialist in Endocrinology & Metabolism, a Diplomate of the American Board of Obesity Medicine, and a Clinical Lecturer at the University of Calgary, Canada. After completing my training as an Endocrinologist in 2005 at the University of Calgary, I have worked in Calgary, at the Royal University Hospital in Saskatchewan, and at the University of Copenhagen in Denmark. I have a busy clinical practice at C-ENDO Diabetes and Endocrinology Clinic in Calgary, caring for patients with diabetes, obesity, thyroid, and other hormone issues. I am also involved in clinical research in diabetes and obesity. I am the lead author of the 2020 and 2022 Pharmacotherapy Chapters of the Canadian Obesity Clinical Practice Guidelines, and a member of the Expert Committee for the Diabetes Canada Clinical Practice Guidelines as an author on the Weight Management chapter. I am passionate, enthusiastic, and driven to help conquer the stigma against obesity; educate health care professionals and the public about obesity and diabetes; and to help us become a healthier society!